drugset / Trial / NCT00562887
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.
Timeline
- Start
- 2007-11
- Primary completion
- 2010-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | briakinumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | briakinumab | Monoclonal antibody | 700 mg | Intravenous |